Global Markets Direct’s, 'Dental Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dental Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Pain. Dental Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Dental Pain. - A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dental Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dental Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dental Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Dental Pain - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dental Pain Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Dental Pain 7 Dental Pain Therapeutics under Development by Companies 9 Late Stage Products 10 Comparative Analysis 10 Mid Clinical Stage Products 11 Comparative Analysis 11 Early Clinical Stage Products 12 Comparative Analysis 12 Dental Pain Therapeutics - Products under Development by Companies 13 Companies Involved in Dental Pain Therapeutics Development 14 Novartis AG 14 Pfizer Inc. 15 IBSA Institut Biochimique SA 16 NeuroDiscovery Ltd 17 Array BioPharma Inc. 18 Dental Pain - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 ARRY-797 - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 NSL-101 - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 diclofenac sodium - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 SAF-312-A - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 PF-05089771 - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 29B-S - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 18c-S - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 34B-S - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 Dental Pain Therapeutics - Drug Profile Updates 35 Dental Pain Therapeutics - Discontinued Products 36 Dental Pain Therapeutics - Dormant Products 37 Dental Pain - Product Development Milestones 39 Featured News and Press Releases 39 Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac 39 Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 42 Disclaimer 42
List of Tables
Number of Products Under Development for Dental Pain, H1 2013 7 Products under Development for Dental Pain - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Late Stage Development, H1 2013 10 Comparative Analysis by Mid Clinical Stage Development, H1 2013 11 Comparative Analysis by Early Clinical Stage Development, H1 2013 12 Products under Development by Companies, H1 2013 13 Novartis AG, H1 2013 14 Pfizer Inc., H1 2013 15 IBSA Institut Biochimique SA, H1 2013 16 NeuroDiscovery Ltd, H1 2013 17 Array BioPharma Inc., H1 2013 18 Assessment by Monotherapy Products, H1 2013 19 Assessment by Combination Products, H1 2013 20 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Stage and Molecule Type, H1 2013 24 Dental Pain Therapeutics - Drug Profile Updates 35 Dental Pain Therapeutics - Discontinued Products 36 Dental Pain Therapeutics - Dormant Products 37 Dental Pain Therapeutics - Dormant Products (Contd..1) 38
List of Figures
Number of Products under Development for Dental Pain, H1 2013 7 Products under Development for Dental Pain - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Late Stage Products, H1 2013 10 Mid Clinical Stage Products, H1 2013 11 Early Clinical Stage Products, H1 2013 12 Assessment by Monotherapy Products, H1 2013 19 Assessment by Combination Products, H1 2013 20 Assessment by Route of Administration, H1 2013 21 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Molecule Type, H1 2013 23 Assessment by Stage and Molecule Type, H1 2013 24